According to Gram Research analysis of a 2026 randomized crossover trial in iScience, an 8-week Mediterranean-ketogenic diet did not significantly change gut bacteria diversity or gut inflammation markers in people with Parkinson’s disease. The diet modestly lowered certain gut-made fatty acids, and no severe adverse events were reported.
A new trial tested whether a ketogenic-style diet could safely change the gut in people with Parkinson’s disease. Researchers compared an 8-week Mediterranean-ketogenic diet with a Mediterranean diet supplemented with medium-chain triglyceride (MCT) oil, with an 8-week break between the two. According to research reviewed by Gram, neither diet meaningfully changed gut bacteria diversity, gut lining leakage, or key gut inflammation markers. The ketogenic diet modestly lowered short-chain fatty acids, which are substances made by gut bacteria. The MCT-supplemented diet was linked to lower blood levels of two inflammation markers. No serious side effects were reported, which suggests larger, longer studies may be worth doing.
Key Statistics
A 2026 randomized crossover trial published in iScience found that an 8-week Mediterranean-ketogenic diet did not significantly change gut microbiome diversity in people with Parkinson’s disease.
A 2026 iScience trial reported that both an 8-week Mediterranean-ketogenic diet and an 8-week MCT-supplemented Mediterranean diet increased the relative abundance of the gut bacterium Roseburia hominis.
In a 2026 randomized crossover trial in iScience, the MCT-supplemented Mediterranean diet was associated with decreases in plasma IL-1β and IL-8, two blood markers of inflammation, over 8 weeks.
A 2026 iScience crossover trial in people with Parkinson’s disease reported no severe adverse events during either 8-week diet phase.
The Quick Take
- What they studied: Can a low-carb, high-fat version of the Mediterranean diet change gut bacteria and gut inflammation in people with Parkinson’s disease, compared with a Mediterranean diet that includes MCT oil?
- Who participated: Adults with Parkinson’s disease took part in the study. The exact number of participants is not stated in the published summary reviewed here, so the size of the group cannot be confirmed.
- Key finding: Neither diet significantly changed gut bacteria diversity, gut lining leakage markers, or key inflammation markers in stool or blood. The ketogenic version modestly reduced certain gut-made substances called short-chain fatty acids, and both diets increased a gut bacterium called Roseburia hominis.
- What it means for you: This study does not show that a ketogenic diet helps Parkinson’s disease. It does suggest the diet did not cause major gut changes or serious side effects over 8 weeks. Anyone considering a major diet change should talk with their neurologist or doctor first.
The Research Details
This was a randomized crossover trial. Randomized means participants were assigned to diets by chance, which helps reduce bias. Crossover means each person tried both diets, one after the other, so each person served as their own comparison.
Participants followed an 8-week Mediterranean-ketogenic diet, which is a Mediterranean-style eating pattern that is very low in carbohydrates and high in fat. After an 8-week break called a washout, they followed an 8-week Mediterranean diet supplemented with MCT oil. MCT stands for medium-chain triglycerides, a type of fat that the body can turn into ketones more quickly than most other fats.
Researchers measured gut bacteria from stool samples, short-chain fatty acids in stool, and blood and stool markers of gut lining leakage and inflammation. Comparing the same people on both diets helps isolate the effect of each diet. The trial is registered under the identifier NCT05469997.
Ketogenic diets have drawn interest for Parkinson’s disease because they may affect brain energy use and inflammation. However, concerns exist that very low-carb diets might disrupt the gut, and the gut is linked to Parkinson’s disease. Testing both diets in the same people, with a washout between them, gives a fairer look at how each one affects the gut than comparing separate groups would.
Randomized crossover trials are a strong design for testing diets because each person acts as their own control. The study is registered, which means its plan was recorded in advance. It was published in iScience, a peer-reviewed journal. The provided summary does not state the number of participants, which is an important detail for judging how precise the results are. Small studies can miss real effects or overstate them, so the findings should be viewed as early evidence.
What the Results Show
The main question was whether either diet changed the gut microbiome, which is the community of trillions of microbes living in the digestive system. Neither diet significantly changed microbiome diversity, meaning how varied the bacterial community was. Neither diet altered the functional genes of the bacteria either, which describe what the microbes are capable of doing. The researchers noted these features are often seen in people with Parkinson’s disease, so the diets did not appear to correct them.
The researchers also checked markers of gut lining leakage and inflammation. Gut lining leakage is sometimes called increased intestinal permeability. They measured zonulin, a protein linked to gut lining leakage, and calprotectin, a marker of gut inflammation. Neither diet significantly changed these markers in stool or blood. This suggests that over 8 weeks, neither diet caused a clear rise in gut lining leakage or gut inflammation.
The ketogenic diet modestly lowered total short-chain fatty acids in stool. These are substances that gut bacteria produce when they break down fiber, and they play roles in gut health and immune function. The change was small, and its meaning for health is not yet clear. Both diets increased the relative share of Roseburia hominis, a gut bacterium that produces short-chain fatty acids.
The MCT-supplemented Mediterranean diet was associated with decreases in two blood inflammation markers, IL-1β and IL-8. These are signaling proteins involved in the body’s immune response. The association was observed in this trial, but it does not prove the diet caused the drop.
No severe adverse events were reported in either diet phase, which is an encouraging safety signal for a short trial. Adverse events are unwanted side effects, and a serious one would be a health problem that requires hospital care or threatens life. Because the trial lasted only 8 weeks per diet, it cannot say whether these results would hold over months or years. The findings about Roseburia hominis and the blood inflammation markers are interesting leads for future research, but they are not strong enough to guide personal choices yet.
Earlier research on ketogenic diets in Parkinson’s disease has focused mostly on symptoms, brain energy, and general safety, and results have been mixed. Many studies of very low-carb diets in other conditions have reported changes in gut bacteria, which made this trial’s null findings on diversity noteworthy. The idea that ketogenic diets might harm the gut has been a common concern, and this trial found no major gut damage over 8 weeks. Research on MCT oil has suggested it may affect fat metabolism and inflammation, which fits with the lower blood inflammation markers seen here.
The trial lasted only 8 weeks per diet, so it cannot show long-term effects on the gut or on Parkinson’s symptoms. The provided summary does not state how many people took part, which limits how confidently the results can be applied. Diet studies are also hard to blind, since people usually know what they are eating. Stool and blood measures capture only part of the gut picture. The findings about Roseburia hominis and inflammation markers came from measurements that were not designed to prove cause and effect. The trial also did not measure Parkinson’s symptoms directly in the summary provided, so it cannot say whether either diet helps the disease itself.
The Bottom Line
Based on this single trial, the evidence is preliminary. Moderate confidence supports the conclusion that an 8-week Mediterranean-ketogenic diet did not significantly disrupt gut bacteria diversity or gut inflammation markers in people with Parkinson’s disease. Low confidence applies to any claim that the ketogenic diet benefits Parkinson’s symptoms, since this trial did not establish that. The research supports further trials of this diet in larger and longer studies rather than widespread use. Anyone considering changes should discuss them with a healthcare team.
People with Parkinson’s disease, their caregivers, and clinicians who manage their care may find this research useful, especially those interested in diet as a supportive approach. Researchers studying the gut-brain connection will also find the results relevant. People without Parkinson’s disease should not assume these findings apply to them. Anyone with kidney disease, liver problems, diabetes, a history of eating disorders, or who takes medications that interact with diet should seek medical advice before trying a ketogenic or MCT-based diet.
This study measured changes over 8 weeks, so that is the realistic window for the gut changes it observed. Changes in gut bacteria can occur within days to weeks of a major diet shift, but they often take longer to stabilize. Any benefit for Parkinson’s symptoms, if it exists, would likely take months to assess, and this trial did not test that. Larger trials lasting six months or more would be needed to answer those questions.
Frequently Asked Questions
Does a ketogenic diet harm gut bacteria in people with Parkinson’s disease?
A 2026 trial in iScience found that an 8-week Mediterranean-ketogenic diet did not significantly change gut microbiome diversity or key gut inflammation markers. The diet modestly reduced short-chain fatty acids in stool, and the researchers reported no severe adverse events.
Can a ketogenic diet improve Parkinson’s symptoms?
This 2026 trial did not establish that a ketogenic diet improves Parkinson’s symptoms. It studied gut and inflammation markers over 8 weeks. Researchers suggest larger, longer trials are needed before any benefit for Parkinson’s disease can be claimed.
What is MCT oil and did it affect inflammation in the study?
MCT oil contains medium-chain triglycerides, fats the body can convert to ketones quickly. In the 2026 iScience trial, the MCT-supplemented Mediterranean diet was linked to lower blood levels of IL-1β and IL-8, two inflammation markers, though this does not prove cause.
Is a Mediterranean-ketogenic diet safe to try for Parkinson’s disease?
A 2026 trial reported no severe adverse events over 8-week periods, which is encouraging. However, the study was short and small in scope. Anyone with Parkinson’s should consult a neurologist or dietitian before starting a ketogenic diet.
Want to Apply This Research?
- If you are working with your healthcare team on a diet plan, log daily carbohydrate grams, fat grams, and any digestive symptoms such as bloating, constipation, or diarrhea on a 1 to 5 scale. Also record weekly bowel movement frequency. Sharing this data with your clinician can help track how your body responds.
- Use the app to set a consistent daily meal log for at least 4 weeks before making any major diet change, so you have a baseline for comparison. If your care team approves a change, track fiber intake from vegetables, legumes, and whole grains, since fiber feeds the gut bacteria that produce short-chain fatty acids. Avoid making abrupt changes without medical guidance.
- Track diet, digestive symptoms, energy, sleep, and any Parkinson’s symptoms your clinician uses, such as tremor, stiffness, or movement, in a weekly summary. Review trends every 8 weeks, which matches the trial’s timeframe. Bring the data to appointments so that changes can be evaluated with professional input rather than from app data alone.
This article summarizes a single research trial for general education and is not medical advice. The trial was small and short, and its findings do not show that a ketogenic or MCT-based diet treats or slows Parkinson’s disease. People with Parkinson’s disease or other health conditions should talk with their neurologist, doctor, or a registered dietitian before changing their diet, especially if they have kidney, liver, or metabolic conditions or take medications.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.